| Negative effects of anemia on quality of life and its improvement by complete correction of anemia by administration of recombinant human erythropoietin in posttransplant patients. | |
| | |
MedLine Citation:
|
PMID: 19352589 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Anemia is a common complication in posttransplant patients (posttransplant anemia: PTA). We tested the hypothesis that targeting hemoglobin (Hb) over 13.3 g/dl by administration of recombinant human erythropoietin (rHuEPO-ad) has positive impact on quality of life (QOL). METHODS: Twenty-four patients, whose initial Hb and estimated glomerular filtration rate (eGFR) were 10.5 +/- 0.2 g/dl and 48.5 +/- 2.7 ml/(min 1.73 m2), respectively, were enrolled in the present study. Physical and mental QOL in these patients before and after rHuEPO-ad were acquired and summarized as physical summary sore (PSC) and mental summary sore (MSC), respectively, by the 36-item Short Form (SF-36), an international questionnaire for analysis of QOL. RESULTS: Before rHuEPO-ad, posttransplant patients had preserved MSC (54.1 +/- 2.3) but impaired PSC (32.6 +/- 3.2). rHuEPO-ad for 6 months increased their Hb to 13.7 +/- 0.3 g/dl. This was accompanied by improvement of PSC (49.1 +/- 2.1: P < 0.01 versus before rHuEPO-ad). MSC was preserved during rHuEPO-ad (54.4 +/- 1.6: NS versus before rHuEPO-ad). There was inverse correlation between initial PSC or MSC and responses of these parameters to rHuEPO-ad (PSC, P = 0.007; MSC, P = 0.009). Patients whose initial PSC was lower than 39.6 or whose initial MSC was lower than 39.4 were expected to improve their PSC or MSC by more than 10 by rHuEPO-ad. CONCLUSIONS: Anemia in posttransplant patients has negative impacts on their QOL. Scoring mental and physical QOL by SF-36 in posttransplant patients is useful to identify groups of patients whose QOL could be improved by rHuEPO-ad. |
| | |
Authors:
|
Noritaka Kawada; Toshiki Moriyama; Naotsugu Ichimaru; Ryoichi Imamura; Isao Matsui; Yoshitsugu Takabatake; Yasuyuki Nagasawa; Yoshitaka Isaka; Yasuyuki Kojima; Yukito Kokado; Hiromi Rakugi; Enyu Imai; Shiro Takahara |
Related Documents
:
|
1939699 - Intellectual loss in alzheimer's dementia and wais-r intrasubtest scatter. 11493169 - Basal ganglia metabolite abnormalities in minor motor disorders associated with human i... 20491609 - Effect of brain-derived neurotrophic factor val66met polymorphism and serum levels on t... 10932269 - Unilateral spatial neglect in ad: significance of line bisection performance. 1491839 - Cognition and 99tcm-hmpao spect in parkinson's disease. 762369 - Dihydroergotoxine: 6-mg versus 3-mg dosage in the treatment of senile dementia. prelimi... 19570519 - Comparison of quality-of-life instruments in adults with strabismus. 22305109 - Dysfunctional forward model mechanisms and aberrant sense of agency in obsessive-compul... 1141959 - Reversible central nervous system dysfunction in folate deficiency. |
Publication Detail:
|
Type: Clinical Trial; Journal Article Date: 2009-04-08 |
Journal Detail:
|
Title: Clinical and experimental nephrology Volume: 13 ISSN: 1437-7799 ISO Abbreviation: Clin. Exp. Nephrol. Publication Date: 2009 Aug |
Date Detail:
|
Created Date: 2009-08-06 Completed Date: 2009-10-27 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9709923 Medline TA: Clin Exp Nephrol Country: Japan |
Other Details:
|
Languages: eng Pagination: 355-60 Citation Subset: IM |
Affiliation:
|
Department of Nephrology, Osaka University Graduate School of Medicine, Osaka, Japan. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Anemia / blood, drug therapy*, etiology, physiopathology, psychology Biological Markers / blood Creatine / blood Erythropoietin, Recombinant / therapeutic use* Female Glomerular Filtration Rate Hematinics / therapeutic use* Hemoglobins / metabolism Humans Kidney Transplantation / adverse effects* Male Middle Aged Patient Selection Prospective Studies Psychiatric Status Rating Scales Quality of Life* Questionnaires Time Factors Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/Erythropoietin, Recombinant; 0/Hematinics; 0/Hemoglobins; 57-00-1/Creatine |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Sargramostim in patients with Crohn's disease: results of a phase 1-2 study.
Next Document: Prevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticity...